Day One Biopharmaceuticals, Inc. (DAWN) reported a net product revenue of $155.4 million for the year ended December 31, 2025, a significant increase of $98.2 million compared to $57.2 million in 2024. License revenue decreased substantially to $2.8 million from $73.9 million in the prior year, primarily due to the recognition of upfront consideration from the Ipsen License Agreement in 2024. The company's net loss for 2025 was $107.3 million, compared to a net loss of $95.5 million in 2024.
Operating expenses for 2025 totaled $285.9 million, a decrease of $62.5 million from $348.4 million in 2024. Research and development expenses decreased to $148.1 million from $227.7 million, mainly due to lower license-related payments. Selling, general, and administrative expenses increased slightly to $120.6 million from $115.5 million, driven by transaction costs related to the Mersana Therapeutics, Inc. acquisition and increased commercial activities. The company's loss from operations was $(127.8) million, compared to $(217.3) million in the prior year.
Strategic developments in 2025 included Ipsen receiving validation for its Marketing Authorization Application to the EMA for tovorafenib, triggering a $4.0 million milestone payment to XOMA. Tovorafenib was also added to the NCCN adult glioma treatment guidelines. Day One cleared the first cohort in the Phase 1a portion of the DAY301 clinical trial and expects to report initial clinical data in the second half of 2026. The company also completed the acquisition of Mersana Therapeutics, Inc. in January 2026, adding Emiltatug ledadotin (Emi-Le) to its oncology portfolio.
Key operational developments included the ongoing Phase 3 FIREFLY-2 trial for tovorafenib, with patient enrollment continuing across multiple global sites, expected to be completed in the first half of 2026. The company also licensed DAY301 from MabCare Therapeutics, granting Day One exclusive worldwide rights, excluding Greater China, to develop, manufacture, and commercialize the novel ADC. As of December 31, 2025, Day One had 178 full-time employees, with a significant portion engaged in research, development, and technical operations.
Looking ahead, Day One Biopharmaceuticals anticipates continued investment in its pipeline, particularly in the clinical development of tovorafenib, Emi-Le, and DAY301. The company expects to present clinical data for Emi-Le in mid-2026 and for DAY301 in the second half of 2026. Day One held $441.1 million in cash, cash equivalents, and short-term investments as of December 31, 2025, which is expected to fund operations for at least the next twelve months.
About Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc. develops targeted oncology therapies for pediatric and adult cancers. Its core product, tovorafenib, is a brain-penetrant RAF kinase inhibitor targeting RAF-driven tumors, including pediatric low-grade glioma. The company focuses on innovative, first- or best-in-class medicines, leveraging clinical development, strategic partnerships, and licensing to address high unmet medical needs across global markets. Its pipeline includes antibody-drug conjugates and kinase inhibitors for high-impact cancers.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.